Abstract. The aim of this study was to investigate the radiosensitizing effects of arsenic trioxide (As 2 O 3 ) on MCF-7 human breast cancer cells irradiated with 89 strontium chloride ( 89 SrCl 2 ). The 50% inhibitory concentration (IC 50 ) was calculated from results of an MTT assay. The concentration of As 2 O 3 less than 20% IC 50 was selected for subsequent experiments. Cells were treated with As 2 O 3 and 89 SrCl 2 . Morphological changes of cells were observed under an inverted microscope. The radiosensitivity enhancing ratio (SER) was computed based on a clone formation assay. Cell cycle distribution and apoptosis were measured by flow cytometry (FCM). Expression of Bcl-2 and Bax at both the mRNA and protein levels was assessed by RT-PCR and western blotting. The IC 50 of As 2 O 3 at 24 h was 11.7 µM. Doses of As 2 O 3 (1 and 2 µM) were used in combin ation treatments and SER values were 1.25 and 1.79, respectively. As 2 O 3 significantly suppressed cell growth, caused G 2 /M arrest, enhanced cell death and apoptosis induced by 89 SrCl 2 and decreased expression of the Bcl-2 gene. Since expression of Bax was unchanged following treatment, As 2 O 3 effectively reduced the Bcl-2/Bax ratio. As 2 O 3 (1-2 µM) enhances the cytotoxic effects of 89 SrCl 2 on the MCF-7 human breast cancer cell line by inducing G 2 phase delay and promoting apoptosis through the reduction of the Bcl-2/Bax ratio.
Introduction
Breast cancer is one of the most common types of cancer in women and accounts for 7-10% of all diseases. Approximately 40 million people succumb to the disease each year (1). The incidence of breast cancer is rising in China (2) and is threatening to become a severe public health problem. Of patients with breast cancer 60-80% will develop bone metastases during the course of the disease (3) . More than half of these patients will experience persistent and increasing bone pain, which seriously impairs the patient's quality of life.
Radiation therapy is a common option for the treatment of breast cancer. Such therapeutic options include external beam radiation therapy and internal radionuclide therapy. In most breast cancer patients with bone metastases, pain in the bone can be relieved through radiation therapy. However, the benefits of radiation therapy can be limited by damage repair mechanisms, cell repopulation, and radiation-resistant hypoxic tumor cells. The radiosensitivity of tumor cells is an important factor that affects the efficacy of radiotherapy. In 1963, Adams et al (4) used nitroacetophenone to radiosensitize rat hypoxic cells. Following this initial report, many researchers have been developing radiation-sensitizing drugs to improve the efficacy of radiotherapy.
Radiation sensitizing agents are defined as any chemicals or biological reagents that selectively enhance the lethality of radiation on tumor cells or that reduce the radiation resistance of tumor cells. Thus, they improve the effect of radiation therapy. The ideal radiation sensitizer should meet the following criteria (5): (i) the agent should be stable and should not easily react with other substances; (ii) the effective dose should not be toxic or at least tolerable; (iii) the agent should be soluble in water for easy delivery; (iv) even at low doses, the drug should have radiation sensitizing effects in conventional fractionated treatment. However, it is difficult to find radiation sensitizers that fully meet all these criteria. In practice, drugs that enhance radiotherapy and show limited toxicity are often used as radiation sensitizers.
Chemotherapy drugs are the best studied agents for promoting radiosensitivity. However, chemotherapeutic drugs are toxic to normal cells and can have synergistic effects with radiation, often making them intolerable for patients. Therefore, there is still a clear need for novel radiation sensitizers in the clinic.
Arsenic trioxide (As 2 O 3 ) was first used for the treatment of acute promyelocytic leukemia (APL) in 1970, and it was approved by the U.S. Federal Food and Drug Administration (FDA) in 2000. Previous studies (6) (7) (8) found that, in addition to APL, As 2 O 3 is also effective against a number of solid tumors, including esophageal, liver, breast and gastric cancer. Although high doses of As 2 O 3 may show significant toxicity, low doses can have notable antitumor effects, including changing tumor cell cycle distribution, promoting cell differentiation and apoptosis, reducing glutathione levels, directly damaging DNA, and inhibiting tumor angiogenesis (9) (10) (11) (12) . It is possible that As 2 O 3 may also have radiosensitizing effects. In the present study, we examined whether As 2 O 3 could sensitize human MCF-7 breast cancer cells to 89 SrCl 2 β-ray irradiation in vitro and we also investigated the underlying molecular mechanisms.
Materials and methods
Cell line. Human breast cancer MCF-7 cell line was obtained from the experimental center of clinical laboratory diagnostics at Bengbu Medical College. They were cultured in RPMI-1640 medium (Gibco, CA, USA) supplemented with l0% FBS (Gibco) in an incubator with 5% CO 2 and saturated humidity at 37˚C.
MTT assay evaluation of the effects of As 2 O 3 on cell prolifer ation. MCF-7 cells (1.0x10 4 cells per well) were seeded in 96-well plates and cultured for 24 h. The medium was then replaced with the same medium containing As 2 O 3 (Sigma, MO, USA) at concentrations of 0, 0.5, 1, 2, 5, 10, 20, 50 and 100 µM for 24 h (6 wells at each concentration). Following incubation, the medium was removed and 200 µl of fresh medium containing 50 µg/µl MTT (Sigma) was added into each well and incubated for an additional 4 h. Medium was then discarded and 150 µl dimethyl sulfoxide (DMSO, Sigma) was added. Optical density (OD) at 570 nm was measured by DG3022A type Microplate Reader (State-run East China Electronic Tube Factory). The rate of cell proliferation was calculated as follows: (experimental OD value/control OD value) x100%. The experiment was repeated 6 times. Growth curves were plotted; the ordinate and abscissa represent the concentration of As 2 O 3 and the rate of cell proliferation, respectively. According to the curve, the 50% inhibiting concentration (IC 50 ) was calculated. 89 SrCl 2 was added into the 89 SrCl 2 group and the combination group for another 48 h. Medium was then discarded and fresh medium was added into each well. Cells were cultured for a total of 12 days. Subsequently, cells were rinsed with phosphate-buffered saline (PBS), and colonies were fixed with 95% ethanol for 15 min. They were then stained with crystal violet for 20 min and counted under the microscope. Surviva1 fraction, SF = no. of colonies formed/(no. of cells seeded x plating efficiency of the control). The cell survival curve was plotted by the multi-target one hit model (14) . Mean lethal dose (D 0 ), quasi-threshold dose (D q ), extrapolation number (N) and radiosensitivity enhancing ratio (SER) were calculated.
Cell cycle analysis. Cells were harvested and rinsed with PBS. They were fixed with 70% ethanol at 4˚C overnight. The following day, cells were centrifuged and the supernatant was discarded. Pellets were rinsed twice with PBS and incubated with 1.5 µl 25 mg/ml RNase A (Sigma) at 37˚C for 30 min. They were then stained with 12 µl 50 µg/ml PI and protected from light at 4˚C for 30 min. Cell cycle distribution was measured by FACSCalibur type flow cytometer (Becton-Dickinson).
Cell apoptosis analysis. Buffer was prepared according to instructions provided for the Annexin V-FITC/PI apoptosis detection kit (BD Biosciences, USA). Cells were harvested, mixed with 300 µl buffer, incubated in the dark with 5 µl Annexin V-FITC for 15 min, and then mixed with 5 µl PI for 5 min. Cell apoptosis was analyzed by flow cytometry (FCM).
Expression of Bcl2 and Bax mRNA measured by RTPCR.
Total RNA was isolated with TRIzol reagent (Invitrogen, CA, USA) according to the manufacturer's instructions. cDNA was synthesized at 42˚C for 1 h and at 70˚C for 10 min from 4 µg of total RNA using the SuperScript II Reverse Transcriptase (Invitrogen) following the manufacturer's protocol. cDNA was subsequently amplified using Hot-StarTaq DNA Polymerase (Qiagen, Australia) and primers at MyCycler™ type PCR (Bio-Rad, CA, USA). Sequences of the primers are as follows (Shanghai Sangon Biological Engineering Technology and Services Co., Ltd.): GAPDH: 5'-GGGAAGGTGAAGGTCGGAGTC-3' (sense primer), 5'-AGCAGAGGGGGCAGAGATGAT-3' (antisense primer); Bcl-2: 5'-CAGCTGCACCTGACGCCCTT-3' (sense primer), 5'-GCCTCCGTTATCCTGGATCC-3' (antisense primer); Bax: 5'-ACCAAGAAGCTGAGCGAGTGTC-3' (sense primer), 5'-TGTCCAGCCCATGATGGTTC-3' (antisense primer).
The PCR program consisted of initial denaturation at 95˚C for 3 min, followed by 30 cycles of denaturation at 95˚C for 45 sec, annealing for 45 sec at 55˚C (Bcl-2), 58˚C (Bax) or 63˚C (GAPDH) and extension at 72˚C for 1 min. A final extension step at 72˚C for 10 min was included for all primers. PCR products were stored at 4˚C and electrophoresed in agarose gel buffered by 1X TBE at 100 V. Images were captured with an ultraviolet analyzer. The electrophoretic pattern was semi-quantitatively analyzed with SmartView image software, and the ratio of sample intensity to intensity of GAPDH was determined.
Western blot analysis. Protein was extracted from cultured cells and subjected to western blot analysis using specific antibodies to Bcl-2 and Bax. The cells were harvested and rinsed with PBS. Cell extracts were prepared with pre-chilled lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.5% deoxycholate, 1 mM EDTA, 1 mM Na 3 VO 4 , 1 mM NaF, 2% Cocktail) and cleared by centrifugation at 12,000 g for 30 min at 4˚C. The supernatant was collected and total protein concentration was measured using the BCA assay kit (Sigma) according to the manufacturer's instructions. Cellular extract containing 30 µg of total protein was separated by 12% sodium dodecylbenzene sulfonate-polyacrylamide gel electrophoresis (SDS-PAGE), and the protein was transferred to PVDF membrane (Millipore, MA, USA). The membrane was then blocked with TBST (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20) containing 5% w/v non-fat dry milk at 37˚C for 1 h. It was then incubated with mouse anti-human Bcl-2 or Bax antibodies (1:200; Santa Cruz Biotechnology, CA, USA) or β-actin antibody (1:800; Santa Cruz Biotechnology) in TBST at 4˚C overnight. The membrane was washed three times and hybridized with horseradish peroxidase-conjugated sheep anti-mouse IgG (1:2000; Millipore) for 2 h at room temperature. After washing three times for 10 min each with 15 ml TBST, protein bands specific for the antibodies were visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech, NJ, USA) associated with fluorography. The intensity of bands for Bcl-2 and Bax proteins were analyzed with Smart view image software and the relative values of Bcl-2/Bax in different groups were calculated.
Statistics. Data are presented as the mean ± SD. Differences between two groups were determined by a t-test between independent samples using SPSS 11.5 software. The relationship between cell viability and As 2 O 3 concentration was assayed using curvilinear regression and correlation analysis.
Results

Suppression of MCF7 cell proliferation by As 2 O 3 .
We measured MCF-7 cell proliferation 24 h after treatment with multiple concentrations of As 2 O 3 and found that the proliferation of cells was suppressed to varying degrees (Fig. 1) concentration, cells gradually became round and unattached. They showed decreased refractive indexes, increased particles in crystal, vacuole-like structures and partly ruptured nuclear membranes. Additionally, debris appeared around cells, some dead cells were found floating in the medium, soma became round in shape, the chromatin condensed and karyopyknosis and fragmentation occurred. The proliferation of cells in the combination group was significantly suppressed, with increased cell debris, incomplete nuclear membranes and smaller shapes and sizes (Fig. 2) . phases G 0 /G 1 or S of the cell cycle. Cells in the treatment groups were mostly found to be in the G 2 /M phase. In both the As 2 O 3 -treated and 89 SrCl 2 -treated groups, the percentage of cells in G 2 /M phase increased in a dose-dependent manner (compared with control, P<0.05). The percentage of cells in G 2 /M phase in the combination group increased dramatically. This increase was most apparent in the 2 µM As 2 O 3 and 4 Gy 89 SrCl 2 group; 45.8% of the cell population was in G 2 /M. Of note, cells in S phase decreased compared with those in the 89 SrCl 2 group (P<0.05) ( Table Ⅰ) .
Effects of As 2 O 3 and
89 SrCl 2 on MCF7 cell apoptosis. Annexin V-FITC/PI double staining flow cytometry was used to discriminate among live cells, dead cells, and cells during early or late apoptotis (Fig. 5 ). Cells were divided into four subpopulations: live cells with low levels of Annexin V and PI (LL zone), cells in the early apoptotic phase with high levels of Annexin V and low levels of PI (LR zone), cells in the late apoptotic phase, and dead cells with high levels of Annexin V and PI (UR zone). We were also able to identify cells that had experienced mechanical injury during the experiment as having low levels of Annexin V and high levels of PI (UL zone). The spontaneous apoptotic rate of MCF-7 cells in the control was low. MCF-7 cells in the early apoptotic phase could be increased by As 2 O 3 . 89 SrCl 2 increased the percentage of dead MCF-7 cells and increased the number of cells in the late apoptotic phase from (2.1±0.7%) in the control to (20.5±4.3%) in the 4 Gy 89 SrCl 2 group. There was only a limited effect in the early apoptotic phase. In the combination groups, cells in both the early and late apoptotic phases as well as dead cells were all significantly increased. (Fig. 6) .
Data was analysed by Smart view image software, and the relative values (the ratio of the sample intensity to the intensity of GAPDH) of expression of Bcl-2 mRNA in the 4 Gy 89 SrCl 2 group and in the combination group were (27.25±3.56%) and (11.47±2.32%) (P<0.05), respectively. There were no differences in Bax mRNA (P>0.05). Despite this, the ratio of Bcl-2/Bax was significantly altered compared to control (P<0.05). Thus, As 2 O 3 represses Bcl-2 mRNA expression caused by 89 SrCl 2 without affecting the expression of Bax mRNA (Fig. 6, (Fig. 7 , Table Ⅳ ). 
Discussion
Breast cancer is one of the most common types of cancer in women and it is often associated with bone metastases (2,3) . Currently, the common approach for the treatment of bone metastasis is external beam radiation therapy. While this method is relatively effective for a single large metastasis, it is quite poor for the treatment of multiple lesions. Systemic medication (analgesic drug therapy and chemotherapy) has some advantages for patients with multiple bone metastases, but there are other toxic side-effects associated with such therapies. Systemic radionuclide therapy has drawn much attention in the clinic. It is a relatively simple and economical procedure that effectively relieves pain and can target multiple bone metastases with few side-effects. 89 SrCl 2 has been widely and successfully used for the treatment of bone metastases (15) (16) (17) . Similar to calcium, 89 Sr is a nuclide that is commonly found in bone. It is estimated that 30-80% of intravenously injected 89 Sr will aggregate in the bone, especially at sites of active bone formation. Thus, its accumul ation within bone metastases is about 2-25 times higher than it is in normal bone (18) . The physical half-life of 89 Sr is 50.56 days, and its biological half-life in normal bone is 14 days. However, 12-90% of 89 Sr is still retained within bone metastases 3 months after 89 Sr injection. The longterm accumulation of 89 Sr within the bone metastatic lesion is a significant advantage for 89 Sr to treat bone metastases. Physically, 89 Sr emits pure β-rays with an average energy of 1.46 MeV, producing an average range in the bone of only 3 mm. Therefore, 89 Sr can effectively kill tumor cells while limiting its effect on the surrounding bone. This results in the shrinkage or elimination of bone metastases and relief of bone pain. Nevertheless, there are still some patients who do not respond due to radioresistance of tumor cells (19, 20) . Thus, searching for safe and effective radiation sensitizers to improve the efficacy of radiation therapy has become a hot topic in radiation biology.
In recent years, arsenic and some Chinese herbs have been found to have radiosensitizing effects. As 2 O 3 is the main component of Chinese medicine arsenic, which was first used for the treatment of patients with APL; in these patients, the treatment had a beneficial effect. In addition, other studies (21-24) have shown that As 2 O 3 can induce tumor cell apoptosis and inhibit the growth of some solid tumors, including esophageal and liver cancers. This effect is partly due to regulation of cell cycle progression, induction of apoptosis and differentiation, blockage of tumor cell sub-lethal DNA damage repair, reduction of telomerase activity and glutathione content in tumor cells, and inhibition of angiogenesis (25) . Such mechanisms can also enhance the radiosensitivity of tumor cells (26) , providing the theoretical basis for the clinical application of As 2 O 3 as a radiation sensitizer. In this study, we demonstrated that As 2 O 3 dose-dependently inhibits the proliferation of MCF-7 cells in vitro (with IC 50 at 11.7 µM, Fig. 1 ). In our radiosensitizing experiment, we found that there were no significant morphological changes of MCF-7 cells treated with low doses of As 2 O 3 , but obvious changes were observed for the cells exposed to 89 SrCl 2 for 48 h, which was accompanied by cell growth inhibition. When cells were treated with the combination of As 2 O 3 and 89 SrCl 2 treatment, significant cell death, apoptosis and growth inhibition were observed.
Radiation dose-survival curves reflect irradiated cell survival in vitro and accurately determine proliferation and cell death. The parameters D 0 , D q and N can be calculated from the radiation dose-survival curve. The D 0 is the average lethal dose needed to cause cell death; this reflects the degree of cell sensitivity to radiation. The greater the D 0 value, the lower the cell sensitivity to radiation. The threshold dose D q value reflects the repair capacity of cells to sublethal damage and negatively correlates with radiation sensitivity. The N is the extrapolation number, reflecting the number of radiationsensitive areas within the cell or required number of target hits. Any two of the three parameters can be used to reflect the extent of radiation sensitivity of cells (14) .
In our study, we found that compared to 89 SrCl 2 radiation alone, the addition of As 2 O 3 significantly decreased the D 0 and D q values of MCF-7 cells (P<0.05). This translated into radiosensitization ratios of 1.25 and 1.79, respectively, indicating that pretreatment with As 2 O 3 significantly reduces the average lethal dose of MCF-7 cells to 89 SrCl 2 irradiation. Thus, As 2 O 3 significantly increases the radiosensitivity of MCF-7 cells to 89 SrCl 2 irradiation in a dose-dependent manner.
Uncontrolled cell proliferation is one of the prominent features of cancer cells, which may result from deregulated cell cycle control. There are a few key phase regulatory sites that play key roles in the regulation of cell cycle progression. Of these, the regulatory sites at the G 1 /S and G 2 /M phases are the most important (27, 28) . Many anticancer drugs cause cell cycle arrest in the G 1 /S or G 2 /M phases to inhibit tumor prolifer ation (29) . The radiosensitivity of tumor cells is closely related to both their capacity to repair DNA and their phase in the cell cycle. Cells in the G 2 /M phase are most sensitive to radiation; cells in early S phase and G 1 phase are moderately sensitive, and cells in late S phase are least sensitive to radiation (30) . Therefore, an important consideration to improving radio sensitivity and radiotherapy efficacy involves promoting tumor cells to enter the cell cycle but to remain in the G 2 /M phase. In our study, we found that 89 Radiation-induced apoptosis is an important mechanism to kill tumor cells. Thus, inducing apoptosis in tumor cells has become a new strategy in radiation oncology. Apoptosis is also the common pathway by which many antitumor drugs exert their effects. FCM is a common method for studying apoptosis, and it can sensitively and accurately distinguish between early and late phases of apoptotic cells via double staining for Annexin V/ PI (34) . In the present study, we found that 89 SrCl 2 irradiation significantly induced late phase apoptosis and cell death but had little effect on early phase apoptosis of MCF-7 cells. However, addition of As 2 O 3 significantly induced not only late phase apoptosis and cell death but also early phase apoptosis of MCF-7 cells (P<0.01; P<0.05 vs.
89 SrCl 2 treatment only). These results suggest that increasing the sensitivity of MCF-7 cells to 89 SrCl 2 -induced apoptosis might be one of the mechanisms by which As 2 O 3 sensitizes cells to 89 SrCl 2 irradiation. Numerous factors affect the response of tumor cells to radiation, including the ability to repair DNA double strand breaks, transmembrane signal transduction and apoptosisrelated gene expression (35) . Previous studies (36) (37) (38) (39) (40) showed that Bcl-2 and Bax play significant roles in the regulation of apoptosis after irradiation. For example, it has been reported that knockdown of Bcl-2 expression significantly sensitized human PC-3 prostate cancer cells to irradiation (38) . In this study, we found that the expression of Bcl-2 and Bax at both the mRNA and protein levels can be detected in MCF-7 cells without any treatment. Treatment with 2 µM As 2 O 3 or 4 Gy 89 SrCl 2 irradiation reduced the antiapoptotic gene Bcl-2 at both the mRNA and protein levels. This reduction was more significant in the combination group (P<0.05 vs. 4 Gy 89 SrCl 2 group). We did not detect significant changes in Bax expression, but the overall Bcl-2/Bax ration did decrease in the individual experimental groups compared to control. This suggests that the radiosensitizing effect of As 2 O 3 might be due to inhibition of Bcl-2 expression and subsequent reduction of the ratio of Bcl-2/Bax, which increases the sensitivity of MCF-7 cells to 89 SrCl 2 irradiation. Another study showed that with the reduction of the Bcl-2/Bax ratio, the formation of Bax homodimers increases, resulting in an increase of the permeability of the mitochondrial membrane in tumor cells (41) . This leads to the release of cytochrome c, activation of downstream signaling pathways, and activation of caspase family members and apoptosis. Kumagai et al (42) have consistently found that As 2 O 3 -induced apoptosis is correlated with downregulation of Bcl-2 and Bcl-xL expressions in NB4 cells.
In summary, we found that low doses of As 2 O 3 (below 20% of the IC 50 ) significantly enhance the sensitivity of MCF-7 cells to 89 SrCl 2 β-ray irradiation in vitro, which is, at least in part, through inducing G 2 /M cell cycle arrest, downregulating Bcl-2 gene expression, and reducing the ratio of Bcl-2/Bax. Consequently, the overall effect is an increase in cell apoptosis. Further understanding of the underlying molecular mechanisms and exploring the possibility of As 2 O 3 radiosensitization in vivo may have significant clinical implications and provide experimental evidence to improve the radionuclide therapeutic efficacy on malignant bone metastasis.
In conclusion, we demonstrated that 1-2 µM of As 2 O 3 could increase the radiosensitivity of human breast cancer MCF-7 cell line by inducing G 2 phase delay. The lethal effect of 89 SrCl 2 on MCF-7 cells thus was enhanced concomitantly with As 2 O 3 pretreatment. The mechanism could be involved in the raising of the apoptosis rate of cells owing to the reduction of the Bcl-2/Bax rate.
